Clinical trials: Adult Anaplastic Oligodendroglioma
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors
Study of Blood and Cheek Cell Samples From Patients With Glioma
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01009307
- Testing
- polymorphism analysis, laboratory biomarker analysis, medical chart review
- Where
- United States
- Volunteers
- 1,709 people
- Sponsor
- University of California, San Francisco
Brain and Central Nervous System Tumors
Suramin in Treating Patients With Recurrent Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary…
- Trial name
- NCT00002639
- Testing
- chemotherapy, suramin
- Where
- United States
- Sponsor
- Emory University
Brain and Central Nervous System Tumors
Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma
RATIONALE: Collecting fluid from a brain tumor using a small catheter may help doctors learn how much methotrexate gets into the tumor to kill the tumor cells.
- Trial name
- NCT00463008
- Testing
- methotrexate, pharmacological study
- Volunteers
- 12 people
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Stage IV Melanoma
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other…
- Trial name
- NCT00498979
- Testing
- recombinant interferon alfa-2b, cisplatin, sodium stibogluconate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors
MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806
RATIONALE: Diagnostic procedures, such as MRI, may help doctors learn how efaproxiral works in the brain and help plan the best treatment.
- Trial name
- NCT00433472
- Testing
- magnetic resonance imaging (MRI)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Erlotinib and sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given…
- Trial name
- NCT00509431
- Testing
- Erlotinib + Sirolimus
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00354068
- Testing
- imatinib mesylate, temozolomide, pharmacological study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Central Nervous System Tumors, Brain Tumor
Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00400816
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Cleveland Clinic
Brain and Central Nervous System Tumors
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
RATIONALE: Thalidomide may stop the growth of malignant glioma by stopping blood flow to the tumor. Drugs used in chemotherapy, such as procarbazine, work in different ways to stop tumor cells from dividing so they stop growing…
- Trial name
- NCT00079092
- Testing
- procarbazine hydrochloride, thalidomide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors, Metastatic Cancer
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of carmustine followed by surgery in treating patients…
- Trial name
- NCT00009854
- Testing
- carmustine in ethanol, conventional surgery
- Where
- 2 sites in United States
- Sponsor
- Direct Therapeutics
Brain and Central Nervous System Tumors
Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
RATIONALE: Biological therapy uses different ways to stimulate the immune system and stop cancer cells from growing. Cytotoxic T cells combined with interleukin-2 may be an effective treatment for recurrent brain tumors.
- Trial name
- NCT00002572
- Testing
- aldesleukin, muromonab-CD3, therapeutic tumor infiltrating lymphocytes
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Glioma
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00795665
- Testing
- bevacizumab, carmustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, Davis
Brain and Central Nervous System Tumors, Unspecified Adult Solid Tumor, Protocol Specific
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help solid tumor cells develop into normal cells.
- Trial name
- NCT00008086
- Testing
- calcitriol, carboplatin
- Where
- United States
- Sponsor
- University of Pittsburgh
Brain and Central Nervous System Tumors, Psychosocial Effects of Cancer and Its Treatment
Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers
RATIONALE: Yoga, meditation, and breathing exercises may help lower stress and improve quality of life in patients with malignant brain tumors and their family caregivers.
- Trial name
- NCT00376818
- Testing
- exercise intervention, educational intervention, physiologic testing
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors, Lymphoma
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00544284
- Testing
- bortezomib, temozolomide, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352521
- Testing
- bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors.
- Trial name
- NCT00025675
- Testing
- gefitinib
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- CATNON (NCT00626990)
- Testing
- temozolomide, DNA methylation analysis, laboratory biomarker analysis
- Where
- 132 sites in United States, Australia and 10 more
- Volunteers
- 751 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC